Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1982 April; 69(4): 913–919.
PMCID: PMC370145

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.


Mevinolin reduces cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. The safety and effectiveness of this agent was evaluated in a double-blind, placebo-controlled study in 59 healthy men (serum cholesterol 3.88--7.76 mmol/liter) in five centers. Subjects maintained their usual diet and activities. Doses of 6.25, 12.5, 25, or 50 mg twice daily for 4 wk produced mean reductions of total serum cholesterol fo 23--27% [vs. placebo (4%), P less than 0.01]. Mean low density lipoprotein cholesterol fell 35--45%, while high density lipoprotein and very low density lipoprotein cholesterol, and triglycerides were not significantly affected. Mean apolipoprotein B fell 27--34%. 50 mg was not significantly more effective than 6.25 mg. Mevinolin was generally well tolerated, and no serious clinical or laboratory abnormalities occurred. One subject (12.5 mg) was withdrawn because of abdominal pain and diarrhea. These results suggest that if long-term safety can be demonstrated, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase are likely to prove useful in the treatment of hypercholesterolemia.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA. 1972 Aug 14;221(7):661–666. [PubMed]
  • Grundy SM. Treatment of hypercholesterolemia. Am J Clin Nutr. 1977 Jun;30(6):985–992. [PubMed]
  • Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957–3961. [PubMed]
  • Rodwell VW, Nordstrom JL, Mitschelen JJ. Regulation of HMG-CoA reductase. Adv Lipid Res. 1976;14:1–74. [PubMed]
  • Kovanen PT, Bilheimer DW, Goldstein JL, Jaramillo JJ, Brown MS. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci U S A. 1981 Feb;78(2):1194–1198. [PubMed]
  • Tobert JA, Hitzenberger G, Kukovetz WR, Holmes IB, Jones KH. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis. 1982 Jan;41(1):61–65. [PubMed]
  • Blomhoff JP. Serum cholesterol determination by gas-liquid chromatography. Clin Chim Acta. 1973 Jan 24;43(2):257–265. [PubMed]
  • Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 Apr;20(4):470–475. [PubMed]
  • Warnick GR, Albers JJ. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978 Jan;19(1):65–76. [PubMed]
  • Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970 Nov;11(6):583–595. [PubMed]
  • Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973 May;19(5):476–482. [PubMed]
  • Eggstein M. Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. II. Zuverlässigkeit der Methode, andere Neutralfettbestimmungen, Normalwerte für Triglyceride und Glycerin im menschlichen Blut. Klin Wochenschr. 1966 Mar 1;44(5):267–273. [PubMed]
  • Cramp DG, Robertson G. The fluorometric assay of triglyceride by a semiautomated method. Anal Biochem. 1968 Oct 24;25(1):246–251. [PubMed]
  • MATTINGLY D. A simple fluorimetric method for the estimation of free 11-hydroxycorticoids in human plasma. J Clin Pathol. 1962 Jul;15:374–379. [PMC free article] [PubMed]
  • Dyas J, Read GF, Riad-Fahmy D. A simple robust assay for testosterone in male plasma using an 125I-radioligand and a solid-phase separation technique. Ann Clin Biochem. 1979 Nov;16(6):325–331. [PubMed]
  • Hillier SG, Brownsey BG, Cameron EH. Some observations on the determination of testosterone in human plasma by radioimmunoassay using antisera raised against testosterone-3-BSA and testosterone-11 -BSA. Steroids. 1973 May;21(5):735–754. [PubMed]
  • FEW JD. A method for the analysis of urinary 17-hydroxycorticosteroids. J Endocrinol. 1961 Mar;22:31–46. [PubMed]
  • Gray CH, Baron DN, Brooks RV, James VH. A critical appraisal of a method fo estimating urinary 17-oxosteroids and total 17-oxogenic steroids. A memorandum prepared at the request of the clinical Endocrinology Committee of the Medical Research Council. Lancet. 1969 Jan 18;1(7586):124–127. [PubMed]
  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed]
  • Onongbu IC, Lewis B. Lipoprotein fractionation by a precipitation method. A simple quantitative procedure. Clin Chim Acta. 1976 Sep 20;71(3):397–402. [PubMed]
  • Sniderman A, Teng B, Jerry M. Determination of B protein of low density lipoprotein directly in plasma. J Lipid Res. 1975 Nov;16(6):465–467. [PubMed]
  • Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975 Jan 4;1(7897):16–19. [PubMed]
  • Sniderman A, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO., Jr Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A. 1980 Jan;77(1):604–608. [PubMed]
  • AVIGAN J, STEINBERG D, VROMAN HE, THOMPSON MJ, MOSETTIG E. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J Biol Chem. 1960 Nov;235:3123–3126. [PubMed]
  • ACHOR WP, WINKELMANN RK, PERRY HO. Cutaneous side effects from use of triparanol (MER-29): preliminary data on ichthyosis and loss of hair. Proc Staff Meet Mayo Clin. 1961 Apr 26;36:217–228. [PubMed]
  • LAUGHLIN RC, CAREY TF. Cataracts in patients treated with triparanol. JAMA. 1962 Jul 28;181:339–340. [PubMed]
  • Kaneko I, Hazama-Shimada Y, Endo A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem. 1978 Jun 15;87(2):313–321. [PubMed]
  • Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980 Mar;35(3):259–266. [PubMed]
  • Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, Watanabe A, Koizumi J, Takeda R. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981 Aug 27;305(9):478–482. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation